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. Furthermore, as the overall male population ages the prevalence will increase. The International Agency for Research on Cancer reported that prostate cancer accounted for 15% of all cancers diagnosed in men and around 1.1 million men were diagnosed with the disease throughout the world in 2012 alone (see the Prostate Cancer Fact Sheet http://gco.iarc.fr/today/factsheets-cancers?cancer=19&type=0&sex=1). Most of these cancers will have a 3 + 3 = 6 Gleason pattern on diagnosis 2 . Nearly five decades after its original conception, the Gleason grading system remains the cornerstone of the management of patients with prostate cancer 3 . To this day, this histological classification has upheld its position as the principal determinant of disease progression. This prognostic attribute is achieved in a rather unusual way. Most histological grading follows an ordinal scale
Evolution of Gleason grading
The birth of Gleason grading. In 1966, Donald Gleason created a unique grading system for prostate cancer that was entirely derived from architectural features of the disease identifiable using low-powered microscopy 3 . With a five-point scale, patterns 1, 2 and 3 represented tumours that most closely resembled normal prostatic glands and patterns 4 and 5 demonstrated an increasingly abnormal glandular architecture. A derivative of the patterns was constructed from the sum of the two most commonly observed grade patterns and became known as the Gleason score. The original description of this system was based on a study in 270 patients, which a later study in 1974 expanded to include 1,032 men 9 . In his early studies, Donald Gleason reported that he could duplicate his grading scores during re-examination of specimens within ±1 score point in 85% of cases 3, 10 . Furthermore, he reported that his grading score had a strong prognostic value and could predict cancer-specific mortality.
Changes in scoring over time. Many aspects of the clinical management of men with prostate cancer have changed since the conception of the Gleason grading system. To accommodate this change in clinical practice, substantial modifications of this system have occurred 11 . For instance, Gleason pattern 1 and 2 are now considered to represent benign proliferations in most instances. The problem with the low grades 1-3 that led to this re-evaluation concerned their reproducibility. Biopsy samples were based on a transrectal systematic approach that often did not characterize the cancer properly. Assessment of low-grade tumours had the greatest interobserver variability among urological pathologists 12, 13 . In the contemporary assessment of prostatic needle biopsy samples, Gleason grading starts at Gleason pattern 3. Owing to the advent and regular use of immunohistochemistry, many of the specimens originally classified as Gleason pattern 1 would now be regarded as atypical adenomatous hyperplasia 14, 15 . By the turn of the millennia, a proposal was made that Gleason patterns 1 and 2 should not be based on the degree of cytological atypia within the cells of a tumour. The Gleason grading system does not incorporate any information on cytological parameters. Instead, it is principally established on the architectural pattern, size and spacing of the tumour glands rather than the nuclear features of the malignant cells themselves. In addition, the system's prognostic value has remained the same despite changes over time to the way in which grade is determined and score calculated 4 . Over the years, it has become widely accepted that Gleason patterns 1 and 2 diagnosed on prostatic needle biopsy specimens actually represent benign proliferations, such as adenosis or atypical adenomatous hyperplasia. A number of concerns mean that it is now time to evaluate whether Gleason pattern 3 that has been well characterised by modern techniques should be considered similar to patterns 1 and 2 (FIG. 1) . Clearly, a change in designation of Gleason pattern 3 to a noncancer status would have profound consequences. In this Perspective article, we argue that most of these consequences are likely to be beneficial to those men diagnosed with Gleason score 3 + 3 = 6 prostate cancer and the viewpoint of Gleason pattern 3 prostate cancer as a lethal disease is becoming increasingly uncertain [5] [6] [7] [8] . Abstract | Nearly five decades following its conception, the Gleason grading system remains a cornerstone in the prognostication and management of patients with prostate cancer. In the past few years, a debate has been growing whether Gleason score 3 + 3 = 6 prostate cancer is a clinically significant disease. Clinical, molecular and genetic research is addressing the question whether well characterized Gleason score 3 + 3 = 6 disease has the ability to affect the morbidity and quality of life of an individual in whom it is diagnosed. The consequences of treatment of Gleason score 3 + 3 = 6 disease are considerable; few men get through their treatments without sustaining some harm. Further modification of the classification of prostate cancer and dropping the label cancer for Gleason score 3 + 3 = 6 disease might be warranted.
diagnosed as prostate cancer, regardless of the type of specimen, owing to inaccuracies and poor reproducibility between experts 14, 16 . In 2001, the rate of biopsy reports describing Gleason scores of 2-4 was 2.4% and reduced to 0% by 2006 (REFS 17, 18) .
In 2005, an adaptation of the Gleason grading system was accepted at a consensus conference of international experts in urological pathology under the auspices of the International Society of Urological Pathology (ISUP) 15, 19 . This adjustment was made to address areas of debate and the existence of architectural arrangements that the original scoring system had not accounted for, aiming to increase reproducibility and reliability of the evaluation of biopsy specimens. The major changes were the inclusion of poorly formed glands into Gleason pattern 4, which would have previously been designated Gleason pattern ≤3, and the revised definition of Gleason score based on needle biopsy samples, which should always include the highest Gleason pattern detected in a specimen 19 . In addition, the new agreement reclassified irregular cribriform glands from pattern 3 to pattern 4. These modifications resulted in a statistical artefact termed the Will Rogers Phenomenon, with improvement of clinical outcomes in patients with Gleason score 3 + 3 = 6 and 3 + 4 = 7 prostate cancer 20, 21 . This clarification on which architectural elements should be attributed a pattern 4 label effectively removed disease with a poor clinical outcome from Gleason score 3 + 3 = 6. point, several different approaches have been in use. Current procedures include 12-core TRUS biopsy, transperineal template biopsy and biopsy targeted to an imaging-identified lesion [23] [24] [25] . Techniques of prostate TRUS biopsy have progressed from systematic sextant to 12-core biopsies, which demonstrated increased cancer detection rates without increasing morbidity 22 . Increasing the number of biopsy cores increased prostate cancer detection rates, including detection of disease without lethal potential 26 . The underlying error was that biopsy targeting was random rather than basing the biopsy deployment on the phenotype presenting itself. Image-guided biopsy is used in the diagnosis of the majority of all cancer types. The visual area of concern is identified before sampling a specific area of abnormality.
When the Gleason grading system was first described the vast majority of men presented with advanced disease and tissue was obtained using a few large-diameter needles directed into the area of palpable abnormality. Now, most biopsies are performed using thin needles, resulting in specimens that differ from those available when the system was created. The use of thin needles has been shown to decrease infection rates following biopsy but provides less tissue per biopsy core 27 . The biopsy method employed influences whether any Gleason pattern 4, if present, will be detected. A biopsy using a 10-12-core TRUS technique can miss pattern 4 in up to 50% of patients 28 . By contrast, the use of modern MRI-guided techniques results in very few Gleason pattern 4 cancers being missed 29 . The consequence is that upgrading (the finding that Gleason score at definitive pathological assessment following radical prostatectomy is higher than at initial biopsy) is significantly reduced 30 . When standard TRUS biopsy is used during the diagnostic work-up, upgrading occurs in up to 50% of patients 28 , which means that risk stratification at diagnosis was incorrect in half of the patients.
Upgrading
Sampling imprecision and reproducibility. The driving force towards increased sampling density or image-guided biopsy is a result of the desire to reduce diagnostic imprecision. This problem most commonly becomes evident when patients are upgraded or reclassified when the pathological status of their radical prostatectomy specimen is compared to the risk attributed to their In addition, the amendment resulted in an overall reduction in the risk of morbidity and mortality associated with attribution of Gleason pattern 4 compared with the classification used before 2005. Thus, any prediction models based on samples that were histologically graded before 2005 (which includes nearly all models) overestimate the risk associated with Gleason pattern 4 disease that is graded using the post-2005 rules.
The current definition of Gleason pattern 3 consists of disease with discrete glandular units that vary in size and shape within the prostatic stroma 19 . Furthermore, individual tumour acini demonstrate a smooth and usually rounded edge with an intact basement membrane. Gleason pattern 4 describes a disruption to the form associated with pattern 3: the glandular architecture is no longer preserved and the basement membrane is disrupted. In this sense, the threshold between Gleason pattern 3 and pattern 4 is not dissimilar from pTa and pT1 in bladder cancer.
Changes in biopsy techniques.
Over the past century, we have witnessed continued modifications to the process of tissue procurement for analysis by the pathologist. The methods have comprised open biopsy, endoscopic punch biopsy, transperineal (blind or ultra sonographyguided) or transrectal (finger-guided or ultrasonography-guided (TRUS)) biopsy, endoscopic resection and, most recently, image-guided biopsy with or without image registration 22 . At any time disease by the pathological assessment of their biopsy sample [31] [32] [33] . This phenomenon has been found in all investigations of this topic published to date, which report reclassification rates that range between 25% and 50% (REFS 34-37). Reclassification error has been shown to be related to the different manner in which Gleason patterns were declared upon assessment of biopsy specimens compared with the full histopathology available at step-sectioning following radical prostatectomy 33 . Gleason score upgrading, as well as downgrading, is still an important problem when using the latest Gleason system, even when accounting for tertiary Gleason patterns in radical prostatectomy specimens 33 . Upgrading of disease merely represents sampling imprecision as opposed to a mandate for justifying the potential presence of increased-grade disease coexisting in the prostate. The occurrence of upgrading highlights a need for development in the manner of how we obtain tumour specimens and adoption of targeted biopsies using MRI or MRI-ultrasonography fusion, which is expected to be declared the gold-standard procedure 38 . Level 1b evidence now exists that supports the adoption of multiparametric MRI before first prostate biopsy as the standard of care 39 . In the presence of Gleason score 3 + 3 = 6 prostate cancer, upgrading to a higher score should not be used as a rationale for treating patients in whom supposed significant disease has not been histologically confirmed.
In addition, problems regarding the reproducibility of Gleason grading, even among pathologists, have been highlighted 40 , This inconsistency would be a potential source for inconsistent diagnoses of cancer in patients who are found to have prostatic tissue with a Gleason score 3 + 3 = 6. An agreement on even stricter criteria separating Gleason pattern 3 from pattern 4 might be required before we are to consider any changes to the nomenclature of prostate cancer, and could also include a requirement for centralized review of all equivocal specimens.
Capacity of Gleason pattern 3 to progress.
Evidence is accumulating that shows the lacking ability of low-grade prostate cancers to progress to higher-grade disease 41, 42 . One study in 1,207 patients (including 267 men with Gleason score ≤6) who underwent prostatectomy between 1982 and 2004 has reported data suggesting that grade is established early in tumour pathogenesis 41 . very likely to be true and substantiated by the abundance of data of well characterized Gleason pattern 3 disease, which arises from the tens of thousands of men who have been monitored following a radical prostatectomy.
Peter Albertsen was one of the first urologists to alert us to the very low propensity of a prostate-cancer-related death conferred by a historical attribution of Gleason pattern 3 status 45 . His report included data from men whose disease was given a Gleason score 3 + 3 = 6 between 1971 and 1984 and underwent conservative management. At 20 years, the prostate cancer death rate in this group was 30 deaths per 1000 person years -unchanged from the rates at 15 years. Investigators of another study reported on 223 untreated men with localized prostate cancer who were all initially managed with observation and androgen deprivation in the presence of symptomatic cancer progression 46 . During a 30-year surveillance period, 12.3% of 65 patients diagnosed with Gleason score ≤6 disease using the 2005 ISUP criteria died owing to their disease. This proportion translates into 1.4 men out of 1,000 men dying of Gleason score ≤6 prostate cancer if monitored for a 10-year period.
Contemporary cohorts of men with Gleason score 3 + 3 = 6 disease who opted for active surveillance had a cancer-specific survival of >97% with median follow-up periods of 22-82 months 8 . Furthermore, data that suggest inferior outcomes of these men who delay radical therapy is yet to be seen 8 . If the mortality in these men remains stable then, again, the question arises whether Gleason score 3 + 3 = 6 prostate cancer results in any consequential cancer-specific mortality.
In a study from 2015, a team of investigators analysed 1,829 prostatectomy specimens from patients treated between 1992 and 2008, acknowledging in their report that the pathological analyses were not performed according to the 2005 ISUP criteria 47 . In this cohort, 451 patients were identified as having Gleason score 3 + 3 = 6 disease and their 10-year cancer-specific mortality was 0% and 0.5% in patients with a disease volume of <0.5 ml and 0.5-2.49 ml, respectively. This difference in death rates was not statistically significant.
Abundant data exist of disease outcomes of tens of thousands of men with well characterized Gleason pattern 3 prostate cancer who have been monitored after radical prostatectomy 48, 49 . A report on a cohort of nearly 10,000 men who were monitored following radical prostatectomy Previous reports of Gleason pattern 3 progressing to higher grades have now been primarily attributed to the inherent sampling insufficiencies of using conventional TRUS biopsy. In 2014, one team of investigators demonstrated that the progression of Gleason pattern 3 to a higher pattern was a rare occurrence in men on active surveillance when both initial and follow-up targeted biopsies were undertaken in an accurate manner using MRI-ultrasonography fusion techniques 42 . We anticipate that the increased adoption of MRI technology in prostate cancer diagnostics and surveillance will enable us to monitor disease in a more reliable manner previously possible 43 . Then we will truly be able to determine the upgrading capacity of low-grade prostate cancer.
Clinical outcomes
Prostate-cancer-specific mortality. Over the years, a considerable amount of data has accumulated regarding the risk associated with a Gleason pattern 3 attribution. Some important points need to be taken into account when evaluating these data. Any description of data on prostate cancer mortality will, by necessity, be based on patients that were treated around 15-20 years ago, which has two implications.
First, contemporary review of the original pathology results of these men would result in upgrading to a higher Gleason pattern in a moderate proportion of men. If the original assessment result was exclusive pattern 3 then the most probable upgrade would be to a Gleason score of 3 + 4 = 7 (REF 11) . Second, the precision of a biopsy two decades ago would have been substantially lower than today. We can, therefore, be certain that a considerable minority of men who were classified as having exclusive Gleason pattern 3 disease would have had a range of pattern 4 and occasionally pattern 5 tissues 44 . The implication is that the attribution of Gleason pattern 3 at that time was associated with considerably more risk than a contemporary attribution. This knowledge is useful to us in the epidemiological analysis of historical data sets. This systematic bias has the effect of rendering our estimations of risk on historical patients as the likely worst-case scenario, as many of these men would have been designated to have Gleason score >6 disease if present-day grading systems had been used. Increasing amounts of data demonstrate that patients with pure Gleason pattern 3 disease have negligible prostatecancer-specific mortality. This assertion is showed that the cancer-specific mortality was 0.03% in men who had pure Gleason pattern 3 disease in their radical specimens 48 .
The Prostate Cancer Intervention
Taking into account the imprecision of risk attribution in several of these cohorts and noting that, today, many of the investigated specimens would be classified as Gleason score 3 + 4 = 7, this evidence collectively suggests that during a 1-20-year time period pure Gleason pattern 3 disease is associated with a minimal risk of a prostate-cancer-related death.
Metastatic capability. Most deaths from cancer occur as a result of metastasis and metastatic lymphatic involvement is a hallmark of advanced prostate cancer 51, 52 . Presence of lymph node metastasis in patients with prostate cancer is directly associated with a poor prognosis and significantly decreased disease-specific and biochemical-recurrence-free survival 53 .
The notion that Gleason score 3 + 3 = 6 disease has a substantial, or indeed any, ability to metastasise is increasingly being questioned 49, 54 . A large-scale population study published in 2014 investigated the presence of lymph node metastases in patients who underwent radical prostatectomy with lymph node sampling following a diagnosis of Gleason score 6 prostate cancer between 2004 and 2010 (REF. 54 ). Only 0.48% of 21,960 patients were found to have lymph node metastases. This proportion was reduced in data from large academic centres and the authors suggest that the presence of positive lymph nodes in patients diagnosed with Gleason score 6 disease could serve as a proxy for assessing the adherence to the 2005 ISUP criteria 54 . Similarly, investigators in a study from 2012 used the 2005 ISUP Gleason scoring system to evaluate the potential of Gleason score ≤6 disease to metastasize to lymph nodes 49 . Using data from 14,123 patients raised concerns regarding the validity of the authors' findings based on data from a single patient 62, 63 .
Molecular changes of Gleason patterns
In their seminal papers published in 2000 and 2011, Hanahan and Weinberg described the pathogenesis of cancer in six, and subsequently eight, pertinent hallmarks applicable to all variations of this disease 64, 65 . We now have mounting molecular, proteomic and RNA-based evidence demonstrating that Gleason score 3 + 3 = 6 prostate cancer is either failing to adhere to or to possess each of the six original hallmarks of cancer (TABLE 1) 66 . For higher-grade, however, an abundance of evidence exists that those diseases fulfil all six criteria 66 .
Research into the molecular bases of cancers has identified differing and exclusive pathologies between the various grades of numerous genitourinary malignancies [67] [68] [69] . For prostate cancer, genetic and epigenetic evidence is emerging that Gleason score 3 + 3 = 6 disease is a distinct entity in comparison with its higher-grade counterparts 66, [70] [71] [72] . The evolution of normal prostatic tissue to high-grade prostate cancer involves morphological, chromosomal and developmental alterations. Germline mutations and environmental factors lead to synergistic DNA damage and oncogenic mutations that, in turn, prime prostatic tissue to transform into a malignant state. The combination of mutations of intracellular tumour suppressor genes (for example, PTEN and TP53), overexpression of oncogenes (for example, MYC, AKT genes, MTOR and genes encoding other tyrosine kinases) and oncogenic androgen-sensitive fusion products of chromosomal rearrangements (for example, TMPRSS2 and ERG) leads to uncontrolled cell proliferation 73 . Genomic analysis of mRNA expression levels of pure Gleason pattern 3 in comparison with Gleason pattern 4 disease has demonstrated that Gleason pattern 3 tissues are relatively homogenous in the genes that are overexpressed 74, 75 . By contrast, mRNA expression patterns of Gleason pattern 4 tissue are unequivocally varied and incorporate a wide range of overexpressed genes 74, 75 . For Gleason pattern 3 disease, little evidence exists for the presence of subclonal driver mutations and, instead, these tissues have been shown to overexpress genes that primarily control intracellular metabolism. Mutations in Gleason pattern 4 disease who had undergone radical prostatectomy at four large academic centres, the authors identified 22 patients with a positive lymph node. Histopathological re-review was undertaken in 19 of these patients demonstrating that all had a primary, secondary or tertiary Gleason pattern 4 or pattern 5; specimens from three patients were unavailable for re-review and the study was limited by a potential observer bias, as all involved pathologists were aware of the nodal metastatic status of the patients before re-review. In this setting, Gleason pattern 3 disease does not seem associated with a metastatic phenotype.
In patients with confirmed haematogenous prostate cancer metastasis, the skeletal system was affected in 90% of men 55 . However, even before ISUP 2005, <1% of men diagnosed with Gleason score 3 + 3 = 6 disease were shown to have bone metastases 56 . Another study in 178 men with Gleason score 3 + 3 = 6 disease of ≤2.5 cm 3 volume found a biochemical recurrence rate of 0% following radical prostatectomy (median follow-up period 84 months) 57 . These studies highlight that if a malignancy does not possess the ability to metastasize it fails to adhere to the label of lethal entity and, therefore, does not fulfil this classical attribute of cancer.
Two studies from 2013 have suggested that Gleason score 3 + 3 = 6 prostate cancer can indeed metastasize, resulting in lethal disease 58, 59 . Nakabayashi et al. 58 highlighted the small number of Gleason score 3 + 3 = 6 prostate cancer that develops into lethal disease. In their cohort of 662 men, seven men were classified as having died from disease of this grade. Numerous methodological flaws of this study have been pointed out, including a lack of centralized review and absence of the exact characterization of the biopsy samples and pathological techniques used 60 . All these highlighted weaknesses have been accepted by the authors as a limitation to the validity of their conclusion 61 . The widely referenced study by Haffner et al. 59 described a lethal metastatic clone originating from a low-grade primary tumour lesion. Using whole-genome sequencing and molecular pathological analyses the investigators demonstrated that the metastases arose from a focus of Gleason score 3 + 3 = 6 disease. This particular patient did also harbour Gleason pattern 4 disease, but comprehensive sequencing of multiple tumour foci could not be performed, as the prostatic DNA was 20 years old. Several groups have are broadly linked to the overexpression of genes associated with the molecular traits of cancer; that is, those regulating the cell cycle, DNA replication and androgen signalling attenuation 76 . Studying multifocal cancers, one group of researchers demonstrated that Gleason score 3 + 3 = 6 prostate cancer diverges early from its higher-grade and metastatic counterparts 70 . Using laser microdissection and exome sequencing, they found that only 9% of high-confidence somatic mutations in Gleason score 3 + 3 = 6 disease were shared with higher-grade disease, whereas the proportion was 82% when comparing high-grade and metastatic foci from lymph nodes. Notably, mutations in cancer-associated genes and in the tumour suppressor p53 signalling pathway were found exclusively in high-grade foci and metastases.
On a molecular level, using genome-wide DNA sequencing, morphologically normal tissue distant from the primary prostate cancer lesion has been shown to contain high levels of mutations 77 . This finding suggests that the underlying mutational processes in morphologically normal and low-grade prostate cancer tissue are also occurring in higher-grade disease consistent with a field effect. Protocols are in place to evaluate the mutation status in >500 men receiving standard-of-care treatment for castration-resistant disease 78 . These studies might provide a systematic basis to define the broad spectrum of genomic alterations in progressive, lethal disease -an essential step in translating early laboratory-based observations into benefits in patient care 78 . Molecular characterization of prostate cancer is not expected to replace current clinical and pathological information. Instead, incorporation of these additional molecular data into current models might provide a more bespoke treatment plan for each patient 67, 78 .
Parallels with other cancers
Keeping in mind previous adaptations in other genitourinary cancer, the loss of the cancer terminology for pure Gleason pattern 3 prostate cancer certainly would not be a radical step. Furthermore, this change would be in keeping with modifications made for several other solid-organ cancers. For example, numerous calls for ductal carcinoma in situ of the breast to forgo the label of carcinoma have been made, primarily led by a multidisciplinary NIH consensus 79, 80 . Similar to Gleason pattern 3 prostate cancer, this call for relabelling is neoplasia of low malignant potential (PUNLMP) was previously categorized within the spectrum of grade 1 bladder cancer. The 1998 WHO-ISUP meeting recognized and renamed certain low-grade bladder tumours with a particularly good prognosis as PUNLMPs, avoiding the label of cancer 88 . PUNLMPs have been shown to have long-term nonmalignant capacity, as they lack any ability to become muscle-invasive or lethal disease according to the literature, thus, they continue to hold the status of a noncancer entity 89 . Clinical comparisons can be made between PUNLMPs in the bladder and Gleason pattern 3 lesions in the prostate, but on a cellular level differences between the two tumours exist. Gleason pattern 3 disease demonstrates nuclear atypia of a malignant type and no basal cell layer that can be observed for its counterparts with higher grades, which in turn pathologically labels Gleason pattern >3 disease as an invasive disease. Histologically, PUNLMPs resemble an exophytic urothelial papilloma with an increased cellular proliferation that exceeds the thickness of normal urothelium 90 . Their papillary structures are lined by an organized arrangement of urothelial cells that have minimal architectural abnormalities and minimal nuclear atypia 90 . fundamentally driven by the favourable prognosis and behaviour of this particular type of breast cancer.
In the field of endocrine surgery, a subset of papillary carcinoma of the thyroid has been labelled papillary microcarcinoma of the thyroid (PMCT), owing to its relatively indolent behaviour. Similar to Gleason score 3 + 3 = 6 prostate cancer, diagnoses of PMCT have increased, mainly because of more frequent use of ultrasonography-guided fine-needle aspiration biopsy. Numerous studies and national guidelines have advocated discharging patients diagnosed with PMCT from future follow-up monitoring or, at most, mere observation as an appropriate management plan as opposed to invasive surgical therapy [81] [82] [83] . Over the past several decades, an increasing number of people with chronic nonmalignant conditions, such as diabetes, hypertension and hypercholesterolaemia, are considered to be diseased, owing to lowered threshold values for diagnosis 84 . Now, evidence is emerging that instigating treatment modalities for the new diagnoses of these diseases is failing to reduce morbidity and mortality [85] [86] [87] . Urologists specializing in the treatment of superficial bladder cancer succeeded in reclassifying a cancer phenotype to a noncancer phenotype. Papillary urothelial 
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Overtreatment, costs and fear Gleason score 3 + 3 = 6 prostate cancer has been given numerous labels, including low-risk disease, insignificant disease, minimal-risk lesions and indolent lesions of epithelial origin (IDLE) 5, 91 . In this context, dropping the label cancer might not be a radical step.
In oncology, overdiagnosis is defined as the diagnosis of cancers that will not clinically manifest themselves during an individual's lifetime or kill their carrier 92 . Overdiagnosis naturally leads to overtreatment. Little debate exists among experts in the field that the current generation of urologists are overtreating prostate cancer [93] [94] [95] [96] . Clinicians are aware that the lifetime risk of substantial morbidity and mortality of a patient who has been diagnosed with Gleason score 3 + 3 = 6 prostate cancer is minimal. However, when given this diagnosis most men still choose to undergo definitive treatment, despite the evidence that they will hardly benefit 94, 95, 97 . Now, there are signs that this behaviour is starting to change and that strategies such as active surveillance are being more widely adopted than previously 98 . The reasons for this development are complex and include deeply entrenched societal and cultural drivers, as well as more widely acknowledged financial and medico-legal imperatives to treat 97, 99, 100 . is categorized as prognostic Gleason grade group 1; group 2 comprises disease in which a secondary pattern 4 is present in a predominant pattern 3; group 3 includes tumours in which pattern 4 dominates over pattern 3; group 4 is attributed to Gleason score 8 disease; and group 5 is reserved for Gleason score ≥9 disease (FIG. 2) .
Conclusions
We propose that our colleagues at ISUP further modify the classification of prostate cancer and drop the label cancer for Gleason score 3 + 3 = 6 disease. With the increased adoption of image-guided techniques to obtain prostatic tissue in a more accurate manner, the fear of potentially having missed disease of an increased grade will not bias disease reporting.
When a patient is given a diagnosis of well characterized Gleason score 3 + 3 = 6 prostate cancer, he has been labelled with a disease status that is associated with a higher mortality if treated compared with leaving it untreated. In addition, the consequences of treatment are considerable both in economic terms and in its inevitable harms; few men get through their treatments without sustaining some harm. Furthermore, the disease entity that we are describing is distinct from its more aggressive counterpart both morphologically and by modern molecular characterisation. Yet, we insist on using the same descriptor for a disease with a broad range of risk and also invoke the same word that is linked with 50% 1-year survival seen in some cancers, such as pancreatic and lung cancer. The move to a five-stage ordinal scale that places exclusive Gleason pattern 3 disease on the lowest rung of the ladder of risk is a welcome and timely development.
Some of our colleagues who have opposing views might be apprehensive, owing to biopsy sampling imprecision and reproducibility, especially when giving a certain diagnosis of a 'benign' condition following assessment of a needle biopsy sample. Furthermore, in pathological terms, Gleason pattern 3 fulfils multiple criteria of cancer. The large and varied evidence that has accumulated over the past decades combined with the reduction in overall risk associated with Gleason pattern 3 (owing to reclassification) and modern diagnostic precision (virtually eliminating upgrading at radical prostatectomy) suggests that the time has come to relegate well characterized Gleason pattern 3 morphological change to being a potential risk factor for cancer -namely Gleason pattern 4 and pattern 5 -and not cancer in its own right.
Overtreatment occurs in 67% of men diagnosed with low-risk prostate cancer and is positively associated with being married and residing in affluent areas 97 . One study found that 64.3% of a cohort of 39,803 men diagnosed with Gleason score ≤6 disease underwent some form of aggressive treatment 101 . Receiving aggressive treatment was significantly associated with men who had a high socioeconomic status, were Caucasian or married. The findings of this study have led to calls for future policies to provide more rigid guidelines for the deferred treatment of Gleason score 3 + 3 = 6 prostate cancer and to offer more culturally and sociodemographically tailored counselling for those men at greatest risk of overtreatment 101 . Calculations for the USA show that the ability to avoid treating men with low-grade prostate cancer who will never succumb to their disease will save US$1.32 billion alone and, more importantly, avoid the marked detrimental effect on patients' quality of life owing to the treatment modalities 97 . A fear of litigation associated with relabelling Gleason score 3 + 3 = 6 prostate cancer as noncancer might exist among pathologists and urologists 100 . Indeed, the most common reason for nonoperative claims in urology is related to the failure to diagnose or treat cancer 102 . Concerns have been raised that pathologists could potentially be a new group of clinicians who are regularly affected by medical liability claims 100, 103 . The majority of men visiting their urologist because of lower urinary tract symptoms are worried about a diagnosis of prostate cancer above all else 104 . When a man is diagnosed with Gleason score 3 + 3 = 6 disease psychological factors of the patient have been shown to drive disease management towards radical treatment 105 . Men of any age have an inherent fear of dying when faced with a diagnosis of prostate cancer 100, 106 . The question arises whether a substantial number of men would still choose to undergo radical treatment if they were presented with the same prognostic and trifecta statistics but dropping the word cancer from their diagnosis of Gleason 3 + 3 = 6 disease.
The grade group system
The most recent modification to the Gleason grading system was an attempt to create a five-point scale to reflect the range of risk 107 . We welcome this new system and look forward to its implementation. The new system comprises a five-stage ordinal scale: exclusive Gleason pattern 3 
